1CDC 2005, Centers for Disease Control, Prevention and Control of Influenza Recommendations of the Advisory Committee on Immunization Practices (ACIP), MWR, 2005, 54 (RR08) : 1 -40.
2Simonson L . Pandemic influenza and mortality: past evidence and projections for the future. In: Board on Global Health. The threat of pandemic influenza :Are we ready?The National Academies Press ,2004.
3Palese P. Making better influenza virus vaccine? Emer Infect Dis, 2006, 12:61-65.
4Kilbourne ED. Future influenza vaccines and the use of genetic recombinants. Bull World Health Organ, 1969, 41:643 -645.
5Stoddard J, Lee MS, Walker RE, et al. Crossproteetion against antigenic variants induced by live - attenuated influenza vaccine in children. In: Pediatric Academic Societies Annual Meeting, Washing ton, DC, 2005. 14 -17.
6Pracci L, Canini I, Puzelli S, et al. Type Ⅰ IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level. Vaccine, 2005, 23 : 2994 -3004.
7Fedson DS. Preparing for pandemic vaccination: an international policy agenda for vaccine development. J Public Health Policy, 2005, 26:4-29.
8Solorzano A, Webby R.J, Lager KM, et al. Mutations in the NS1 protein of swine influenza virus impair anti - interferon activity and confer attenuation in pigs. J Virol, 2005, 79:7535 -7543.
9Ferko B, Stasakova J, Romanova J, et al. lmmunogenicity and protection efficacy of replication - deficient influenza A viruses with altered NS1 genes. J Virol, 2004, 78:13037 -13045.
